Post by itchin4answers on Oct 18, 2015 17:00:06 GMT -5
Emerging Diseases
Thirty previously unknown diseases, such as HIV/AIDS, Ebola, hepatitis C, Lyme disease, hantavirus pulmonary syndrome and Severe Acute Respiratory Syndrome (SARS) have emerged in the past 20 years. They remain incurable. These emerging diseases represent a significant cause of suffering and death, and impose an enormous financial burden on society. Studies show that pandemics of new strains of influenza and other emerging diseases are travelling faster and wider than ever before owing to global travel and trade. Some “older” diseases have been effectively controlled with the help of modern technologies, such as antibiotics and vaccines; others, such as malaria, TB and bacterial pneumonia, are now re-emerging in forms resistant to drug treatments (see anti-microbial resistance).
www.who.int/trade/glossary/story022/en/
Infections with the tick-borne bacterium "Candidatus Neoehrlichia mikurensis" mimic noninfectious conditions in patients with B cell malignancies or autoimmune diseases.
Abstract
BACKGROUND:
Candidatus Neoehrlichia mikurensis is a newly discovered noncultivatable bacterium spread among ticks and rodents in Europe and Asia that can infect humans, particularly immunocompromised patients.
www.ncbi.nlm.nih.gov/pubmed/24647019
WHO Director-General addresses G7 health ministers meeting on antimicrobial resistance
Dr Margaret Chan
Director-General of the World Health Organization
Remarks at the G7 Health Ministers Meeting. Session on antimicrobial resistance: realizing the "one health” approach. Berlin, Germany
8 October 2015
Honourable ministers, ladies and gentlemen,
The rise of antimicrobial resistance is a global health crisis. Medicine is losing more and more mainstay antimicrobials as pathogens develop resistance. Second-line treatments are less effective, more costly, more toxic, and sometimes extremely difficult to administer. Many are also in short supply.
Superbugs haunt hospitals and intensive care units all around the world. Gonorrhoea is now resistant to multiple classes of drugs. An epidemic of multidrug-resistant typhoid fever is rolling across parts of Asia and Africa. Even with the best of care, only around half of all cases of multidrug- resistant tuberculosis can be successfully cured.
With few replacement products in the pipeline, the world is heading towards a post-antibiotic era in which common infections will once again kill.
This will be the end of modern medicine as we know it. If current trends continue, sophisticated interventions, like organ transplantation, joint replacements, cancer chemotherapy, and care of pre-term infants, will become more difficult or even too dangerous to undertake.
Adoption of the WHO Global action plan on antimicrobial resistance at the May World Health Assembly has given concrete expression to this growing level of concern.
The action plan sets out five strategic objectives: to improve awareness, to strengthen surveillance and research, to reduce infections in the first place, to use these medicines wisely, and to ensure sustainable investment, also in R&D for replacement products and better diagnostic tools.
Evidence that resistance is driven by the volume of antimicrobial use is compelling. High antibiotic use can arise from overprescribing, easy access through over-the-counter sales, sales via the internet, or pressure from patients.
Decisions to prescribe antibiotics, in human and veterinary medicine, are rarely based on a definitive diagnosis. Having rapid, low-cost, and readily available diagnostic tests could help, but will not solve all problems.
For example, rapid and reliable tests for malaria are available, but fragile antimalarial drugs are still handed out, in many endemic countries, to any child with a fever. This practice, too, hastens the development of drug resistance.
Overprescribing also occurs in animal husbandry and agriculture, and in the food industry, especially when massive quantities of antibiotics are used to promote growth, not to treat sick animals. Routine use of antibiotics at sub-therapeutic levels kills the weakest bacteria, but lets the more resistant ones survive.
Farmers working with cattle, pigs, and poultry infected with drug-resistant bacteria are at much higher risk of being colonized or infected with these bacteria. In addition, human consumption of food carrying antibiotic-resistant bacteria can lead to the acquisition of a drug-resistant infection.
The World Economic Forum has identified antibiotic resistance as a global risk beyond the capacity of any organization or nation to manage or mitigate alone.
At the international level, WHO collaborates closely with the International Organization for Animal Health, or OIE. Relevant sections in OIE standard-setting codes promote the responsible and prudent use of antimicrobials to preserve their therapeutic efficacy and prolong their use in both veterinary and human medicine.
In another mutually reinforcing activity, the WHO list of critically important antimicrobials for human health is paralleled by an OIE list of antimicrobial agents of veterinary importance, which recommends the restricted use of certain agents.
In 2008, WHO established an advisory group on integrated surveillance of antimicrobial resistance associated with the use of antibiotics in food-producing animals. This advisory group adds support to OIE standards for monitoring the quantities of antimicrobials used and the extent of resistance. Specifically, it helps formulate and prioritize risk assessment and risk management strategies.
As in public health, authorities responsible for animal health face a number of obstacles, including poor regulatory control and large quantities of adulterated or substandard products circulating in world trade or readily purchased via the internet.
Ladies and gentlemen,
I have a final comment.
Consumer groups and civil society can play an important role in combating antimicrobial resistance. They are important movers, shakers, and front-line players, especially in this age of social media.
Consumers who question the safety of food produced from heavily-medicated animals, and make purchasing decisions accordingly, can have a profound impact on industry practices.
Thank you.
www.who.int/dg/speeches/2015/g7-antimicrobial-resistance/en/
Thirty previously unknown diseases, such as HIV/AIDS, Ebola, hepatitis C, Lyme disease, hantavirus pulmonary syndrome and Severe Acute Respiratory Syndrome (SARS) have emerged in the past 20 years. They remain incurable. These emerging diseases represent a significant cause of suffering and death, and impose an enormous financial burden on society. Studies show that pandemics of new strains of influenza and other emerging diseases are travelling faster and wider than ever before owing to global travel and trade. Some “older” diseases have been effectively controlled with the help of modern technologies, such as antibiotics and vaccines; others, such as malaria, TB and bacterial pneumonia, are now re-emerging in forms resistant to drug treatments (see anti-microbial resistance).
www.who.int/trade/glossary/story022/en/
Infections with the tick-borne bacterium "Candidatus Neoehrlichia mikurensis" mimic noninfectious conditions in patients with B cell malignancies or autoimmune diseases.
Abstract
BACKGROUND:
Candidatus Neoehrlichia mikurensis is a newly discovered noncultivatable bacterium spread among ticks and rodents in Europe and Asia that can infect humans, particularly immunocompromised patients.
www.ncbi.nlm.nih.gov/pubmed/24647019
WHO Director-General addresses G7 health ministers meeting on antimicrobial resistance
Dr Margaret Chan
Director-General of the World Health Organization
Remarks at the G7 Health Ministers Meeting. Session on antimicrobial resistance: realizing the "one health” approach. Berlin, Germany
8 October 2015
Honourable ministers, ladies and gentlemen,
The rise of antimicrobial resistance is a global health crisis. Medicine is losing more and more mainstay antimicrobials as pathogens develop resistance. Second-line treatments are less effective, more costly, more toxic, and sometimes extremely difficult to administer. Many are also in short supply.
Superbugs haunt hospitals and intensive care units all around the world. Gonorrhoea is now resistant to multiple classes of drugs. An epidemic of multidrug-resistant typhoid fever is rolling across parts of Asia and Africa. Even with the best of care, only around half of all cases of multidrug- resistant tuberculosis can be successfully cured.
With few replacement products in the pipeline, the world is heading towards a post-antibiotic era in which common infections will once again kill.
This will be the end of modern medicine as we know it. If current trends continue, sophisticated interventions, like organ transplantation, joint replacements, cancer chemotherapy, and care of pre-term infants, will become more difficult or even too dangerous to undertake.
Adoption of the WHO Global action plan on antimicrobial resistance at the May World Health Assembly has given concrete expression to this growing level of concern.
The action plan sets out five strategic objectives: to improve awareness, to strengthen surveillance and research, to reduce infections in the first place, to use these medicines wisely, and to ensure sustainable investment, also in R&D for replacement products and better diagnostic tools.
Evidence that resistance is driven by the volume of antimicrobial use is compelling. High antibiotic use can arise from overprescribing, easy access through over-the-counter sales, sales via the internet, or pressure from patients.
Decisions to prescribe antibiotics, in human and veterinary medicine, are rarely based on a definitive diagnosis. Having rapid, low-cost, and readily available diagnostic tests could help, but will not solve all problems.
For example, rapid and reliable tests for malaria are available, but fragile antimalarial drugs are still handed out, in many endemic countries, to any child with a fever. This practice, too, hastens the development of drug resistance.
Overprescribing also occurs in animal husbandry and agriculture, and in the food industry, especially when massive quantities of antibiotics are used to promote growth, not to treat sick animals. Routine use of antibiotics at sub-therapeutic levels kills the weakest bacteria, but lets the more resistant ones survive.
Farmers working with cattle, pigs, and poultry infected with drug-resistant bacteria are at much higher risk of being colonized or infected with these bacteria. In addition, human consumption of food carrying antibiotic-resistant bacteria can lead to the acquisition of a drug-resistant infection.
The World Economic Forum has identified antibiotic resistance as a global risk beyond the capacity of any organization or nation to manage or mitigate alone.
At the international level, WHO collaborates closely with the International Organization for Animal Health, or OIE. Relevant sections in OIE standard-setting codes promote the responsible and prudent use of antimicrobials to preserve their therapeutic efficacy and prolong their use in both veterinary and human medicine.
In another mutually reinforcing activity, the WHO list of critically important antimicrobials for human health is paralleled by an OIE list of antimicrobial agents of veterinary importance, which recommends the restricted use of certain agents.
In 2008, WHO established an advisory group on integrated surveillance of antimicrobial resistance associated with the use of antibiotics in food-producing animals. This advisory group adds support to OIE standards for monitoring the quantities of antimicrobials used and the extent of resistance. Specifically, it helps formulate and prioritize risk assessment and risk management strategies.
As in public health, authorities responsible for animal health face a number of obstacles, including poor regulatory control and large quantities of adulterated or substandard products circulating in world trade or readily purchased via the internet.
Ladies and gentlemen,
I have a final comment.
Consumer groups and civil society can play an important role in combating antimicrobial resistance. They are important movers, shakers, and front-line players, especially in this age of social media.
Consumers who question the safety of food produced from heavily-medicated animals, and make purchasing decisions accordingly, can have a profound impact on industry practices.
Thank you.
www.who.int/dg/speeches/2015/g7-antimicrobial-resistance/en/